※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
암치료용 유전체학 시장의 성장과 동향 :
Grand View Research, Inc.의 최신 보고서에 따르면, 암치료용 유전체학 세계 시장 규모는 2030년까지 509억 7,000만 달러에 이를 전망입니다.
2024년부터 2030년까지의 CAGR은 16.0%로 확대될 것으로 예측됩니다. 암 유병률 증가는 진단과 치료를 위한 차세대 시퀀싱의 채용과 함께 향후 성장 기회로 시장에 박차를 가할 것으로 예상됩니다. 암 이환율 증가는 향후 수년간 비용 효율적인 정확한 진단에 대한 수요를 유발합니다.
게다가 치료 표적을 특정하기 위한 암의 분자 특성 해석에 있어서의 맞춤형 의료에 대한 수요 증가가 시장 성장의 요인이 되고 있습니다. 마찬가지로, 유전체 시퀀싱의 비용 절감, 헬스케어 지출 증가, 암의 효과적인 진단·치료법의 개발 등의 요인도, 암 의료에 있어서의 유전체학의 잠재적 성장의 원인이 되고 있습니다.
암치료용 유전체학 시장 보고서 하이라이트
- 2023년 시점의 판매 점유율에서 장비 분야는 전체 시장의 54.8%를 차지하며 이는 장비와 관련된 높은 비용 때문입니다. 한편, 소모품은 유전체 검사에서 가장 널리 사용되는 제품 분야입니다.
- 차세대 시퀀싱, PCR, 기타 암 리스크 관리 및 유전자 검사 등의 서비스 수요는 유전체 분석을 위한 아웃소싱 활동 증가로 예측 기간 동안 확대될 것으로 예상됩니다. 유전학적 검사를 수행하는 데 드는 높은 비용과 이러한 기술을 사용하여 관련 이익에 대한 의식이 증가하는 것은 이 부문에 영향을 미치는 큰 렌더링 촉진요인입니다.
- 창약·개발분야는 암의 효과적인 치료에 대한 수요 증가와 신제품 개발을 위한 제조업체에 의한 바이오의약품에 대한 투자 증가로 예측 기간 동안 18.5%의 유리한 CAGR을 나타냈다고 예상됩니다.
목차
제1장 조사 방법과 범위
제2장 주요 요약
제3장 암치료용 유전체학 시장의 변수, 동향, 범위
- 시장 소개/계통 전망
- 시장 규모와 성장 전망
- 시장 역학
- 시장 성장 촉진요인 분석
- 시장 성장 억제요인 분석
- 암치료용 유전체학 시장 분석 툴
- Porter's Five Forces 분석
- PESTEL 분석
제4장 암치료용 유전체학 시장 : 제품별 추정·동향 분석
- 부문 대시보드
- 암치료용 유전체학 시장 : 제품별 변동 분석, 2023년 및 2030년
- 기기
- 소모품
- 서비스
제5장 암 의료에 있어서의 유전체학 시장 : 용도별 추정·동향 분석
- 부문 대시보드
- 암치료용 유전체학 시장 : 용도별 변동 분석, 2023년 및 2030년
- 진단
- 맞춤형 의료
- 의약품의 발견과 개발
- 조사
제6장 암치료용 유전체학 시장 : 기술별 추정·동향 분석
- 부문 대시보드
- 암치료용 유전체학 시장 : 기술별 변동 분석, 2023년 및 2030년
- 유전체 서열 분석
- PCR
- 마이크로어레이
- 핵산 추출 및 정제
- 기타
제7장 암치료용 유전체학 시장 : 지역별 추정·동향 분석
- 암치료용 유전체학 시장 점유율, 지역별, 2023년 및 2030년
- 북미
- 유럽
- 아시아태평양
- 라틴아메리카
- 중동 및 아프리카
- 사우디아라비아
- 아랍에미리트(UAE)
- 남아프리카
제8장 경쟁 구도
- 주요 시장 진출기업에 의한 최근의 동향과 영향 분석
- 기업 분류
- 기업 히트맵 분석
- 기업 프로파일
- Agilent Technologies, Inc.,
- F. Hoffmann-La Roche Ltd
- Beckman Coulter, Inc.,
- Illumina Inc.
- Abbott
- Cancer Genetics Inc.
- Bio-Rad Laboratories
- PacBio
- GE Healthcare
- Quest Diagnostics Incorporated
- PerkinElmer
- Luminex
JHS 24.09.24
Genomics In Cancer Care Market Growth & Trends:
The global genomics in cancer care market size is expected to reach USD 50.97 billion by 2030, according to a new report by Grand View Research, Inc. It is projected to expand at a CAGR of 16.0% from 2024 to 2030. Increasing prevalence of cancer coupled with adoption of next generation sequencing for the diagnosis & treatment is expected to fuel the market with future growth opportunities. Increasing incidences of cancer triggers the demand for cost effective and accurate diagnostics in coming years.
In addition, increasing demand for personalized medicines in molecular characterization of cancer to identify therapeutic targets is the factor attributing towards the market growth. Similarly, factors such as cost reduction in genome sequencing, growing healthcare expenditure levels and development of effective diagnostics & therapeutic procedures for cancer are responsible for the potential growth of genomics in cancer care.
Genomics In Cancer Care Market Report Highlights:
- Instrument segment dominated the overall market in terms of revenue share as of 2023 and accounted for 54.8% of market owing to high cost associated with it. Whereas, consumables are most widely used product segment in genome testing as they are indispensible component and frequently required to perform the test.
- Demand for services such as next generation sequencing, PCR and other such as cancer risk management & genetic testing are expected to grow over the forecast period due to increasing outsourcing activities to perform genome analysis. High cost of performing genetic tests and growing awareness pertaining to associated benefits with the use of these technologies are high impact rendering drivers for this segment.
- Drug discovery and development segment is expected to show lucrative CAGR of 18.5% during the forecast period owing to increasing demand for effective treatment for cancer and growing investment in biomedicines by manufacturers for the development of novel products.
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Market Definitions
- 1.3. Research Methodology
- 1.3.1. Information Procurement
- 1.3.2. Information or Data Analysis
- 1.3.3. Market Formulation & Data Visualization
- 1.3.4. Data Validation & Publishing
- 1.4. Research Scope and Assumptions
- 1.4.1. List of Data Sources
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Insights
Chapter 3. Genomic in Cancer Care Market Variables, Trends, & Scope
- 3.1. Market Introduction/Lineage Outlook
- 3.2. Market Size and Growth Prospects (USD Million)
- 3.3. Market Dynamics
- 3.3.1. Market Drivers Analysis
- 3.3.2. Market Restraints Analysis
- 3.4. Genomic in Cancer Care Market Analysis Tools
- 3.4.1. Porter's Analysis
- 3.4.1.1. Bargaining power of the suppliers
- 3.4.1.2. Bargaining power of the buyers
- 3.4.1.3. Threats of substitution
- 3.4.1.4. Threats from new entrants
- 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
- 3.4.2.1. Political landscape
- 3.4.2.2. Economic and Social landscape
- 3.4.2.3. Technological landscape
- 3.4.2.4. Environmental landscape
- 3.4.2.5. Legal landscape
Chapter 4. Genomics in Cancer Care Market: Product Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Genomics in Cancer Care Market: Product Movement Analysis, 2023 & 2030 (USD Million)
- 4.3. Instruments
- 4.3.1. Instruments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.4. Consumables
- 4.4.1. Consumables Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.5. Services
- 4.5.1. Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Genomics in Cancer Care Market: Application Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Genomics in Cancer Care Market: Application Movement Analysis, 2023 & 2030 (USD Million)
- 5.3. Diagnostics
- 5.3.1. Diagnostics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.4. Personalized Medicine
- 5.4.1. Personalized Medicine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.5. Drug Discovery & Development
- 5.5.1. Drug Discovery & Development Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.6. Research
- 5.6.1. Research Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Genomics in Cancer Care Market: Technology Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. Genomics in Cancer Care Market: Technology Movement Analysis, 2023 & 2030 (USD Million)
- 6.3. Genome Sequencing
- 6.3.1. Genome Sequencing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.4. PCR
- 6.4.1. PCR Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.5. Microarrays
- 6.5.1. Microarrays Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.6. Nucleic Acid Extraction & Purification
- 6.6.1. Nucleic Acid Extraction & Purification Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.7. Other
- 6.7.1. Other Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Genomics in Cancer Care Market: Regional Estimates & Trend Analysis
- 7.1. Genomics in Cancer Care Market Share, By Region, 2023 & 2030 (USD Million)
- 7.2. North America
- 7.2.1. North America Genomics in Cancer Care Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.2. U.S.
- 7.2.2.1. U.S. Genomics in Cancer Care Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.3. Canada
- 7.2.3.1. Canada Genomics in Cancer Care Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.4. Mexico
- 7.2.4.1. Mexico Genomics in Cancer Care Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3. Europe
- 7.3.1. Europe Genomics in Cancer Care Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.2. U.K.
- 7.3.2.1. U.K. Genomics in Cancer Care Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.3. Germany
- 7.3.3.1. Germany Genomics in Cancer Care Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.4. France
- 7.3.4.1. France Genomics in Cancer Care Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4. Asia Pacific
- 7.4.1. Asia Pacific Genomics in Cancer Care Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.2. China
- 7.4.2.1. China Genomics in Cancer Care Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.3. Japan
- 7.4.3.1. Japan Genomics in Cancer Care Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.4. India
- 7.4.4.1. India Genomics in Cancer Care Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.5. South Korea
- 7.4.5.1. South Korea Genomics in Cancer Care Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.6. Australia
- 7.4.6.1. Australia Genomics in Cancer Care Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5. Latin America
- 7.5.1. Latin America Genomics in Cancer Care Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.2. Brazil
- 7.5.2.1. Brazil Genomics in Cancer Care Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6. Middle East and Africa
- 7.6.1. Middle East and Africa Genomics in Cancer Care Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.2. Saudi Arabia
- 7.6.2.1. Saudi Arabia Genomics in Cancer Care Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.3. UAE
- 7.6.3.1. UAE Genomics in Cancer Care Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.4. South Africa
- 7.6.4.1. South Africa Genomics in Cancer Care Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
- 8.1. Recent Developments & Impact Analysis by Key Market Participants
- 8.2. Company Categorization
- 8.3. Company Heat Map Analysis
- 8.4. Company Profiles
- 8.4.1. Agilent Technologies, Inc.,
- 8.4.1.1. Participant's Overview
- 8.4.1.2. Financial Performance
- 8.4.1.3. Product Benchmarking
- 8.4.1.4. Recent Developments/ Strategic Initiatives
- 8.4.2. F. Hoffmann-La Roche Ltd
- 8.4.2.1. Participant's Overview
- 8.4.2.2. Financial Performance
- 8.4.2.3. Product Benchmarking
- 8.4.2.4. Recent Developments/ Strategic Initiatives
- 8.4.3. Beckman Coulter, Inc.,
- 8.4.3.1. Participant's Overview
- 8.4.3.2. Financial Performance
- 8.4.3.3. Product Benchmarking
- 8.4.3.4. Recent Developments/ Strategic Initiatives
- 8.4.4. Illumina Inc.
- 8.4.4.1. Participant's Overview
- 8.4.4.2. Financial Performance
- 8.4.4.3. Product Benchmarking
- 8.4.4.4. Recent Developments/ Strategic Initiatives
- 8.4.5. Abbott
- 8.4.5.1. Participant's Overview
- 8.4.5.2. Financial Performance
- 8.4.5.3. Product Benchmarking
- 8.4.5.4. Recent Developments/ Strategic Initiatives
- 8.4.6. Cancer Genetics Inc.
- 8.4.6.1. Participant's Overview
- 8.4.6.2. Financial Performance
- 8.4.6.3. Product Benchmarking
- 8.4.6.4. Recent Developments/ Strategic Initiatives
- 8.4.7. Bio-Rad Laboratories
- 8.4.7.1. Participant's Overview
- 8.4.7.2. Financial Performance
- 8.4.7.3. Product Benchmarking
- 8.4.7.4. Recent Developments/ Strategic Initiatives
- 8.4.8. PacBio
- 8.4.8.1. Participant's Overview
- 8.4.8.2. Financial Performance
- 8.4.8.3. Product Benchmarking
- 8.4.8.4. Recent Developments/ Strategic Initiatives
- 8.4.9. GE Healthcare
- 8.4.9.1. Participant's Overview
- 8.4.9.2. Financial Performance
- 8.4.9.3. Product Benchmarking
- 8.4.9.4. Recent Developments/ Strategic Initiatives
- 8.4.10. Quest Diagnostics Incorporated
- 8.4.10.1. Participant's Overview
- 8.4.10.2. Financial Performance
- 8.4.10.3. Product Benchmarking
- 8.4.10.4. Recent Developments/ Strategic Initiatives
- 8.4.11. PerkinElmer
- 8.4.11.1. Participant's Overview
- 8.4.11.2. Financial Performance
- 8.4.11.3. Product Benchmarking
- 8.4.11.4. Recent Developments/ Strategic Initiatives
- 8.4.12. Luminex
- 8.4.12.1. Participant's Overview
- 8.4.12.2. Financial Performance
- 8.4.12.3. Product Benchmarking
- 8.4.12.4. Recent Developments/ Strategic Initiatives